Race in clinical trials in Sweden: How regulatory and medical standards in clinical research trump the post‐racial discourse

Author:

Mulinari Shai1ORCID,Bredström Anna2ORCID

Affiliation:

1. Department of Sociology Lund University Lund Sweden

2. Institute for Research on Migration, Ethnicity and Society (REMESO) Linköping University Norrköping Sweden

Abstract

AbstractThe post‐racial discourse that permeates many Western European countries depicts society as having moved beyond race concepts and classifications. This article focuses on Sweden, a country that, in line with the post‐racial thinking, declares race to be an offensive and unscientific concept. The article investigates what happens when this post‐racial discourse meets clinical research standards that encourage, if not demand, the collection of data on patient race. Through an analysis of the reporting of patient race in 76 multinational trials with at least one study site in Sweden, and a review of the regulatory and medical standards and trial documents that direct the collection of patient race in trials, we show how race classification is kept intact in trials despite conflicting with post‐racial norms and conventions. Notably, our findings diverge from the way racialisation is typically assumed to work in Sweden and related countries. We argue this is possible because the two incompatible understandings of race are ‘distributed’ (Mol, 2002, The body multiple: Ontology in medical practice, Duke University Press) among different social worlds. The distribution, we propose, is upheld through the paucity of major debate on why and how race classification should be carried out in clinical trials in Europe as this allows contradictions to remain unspoken.

Funder

Vetenskapsrådet

Publisher

Wiley

Subject

Public Health, Environmental and Occupational Health,Health Policy,Health (social science)

Reference82 articles.

1. Invisibility of Racism in the Global Neoliberal Era: Implications for Researching Racism in Healthcare

2. Astellas Pharma. (2007).SmPC: Advagraf prolonged‐release hard capsules.https://www.ema.europa.eu/en/documents/product‐information/advagraf‐epar‐product‐information_en.pdf

3. AstraZeneca. (2019).Statistical analysis plan ‐ Acute STroke or Transient IscHaemic Attack treated with TicAgreLor and ASA for PrEvention of Stroke and Death (THALES).https://clinicaltrials.gov/ct2/show/NCT03354429

4. AstraZeneca. (2021).SmPC: Crestor 5mg film‐coated tablets.https://www.medicines.org.uk/emc/product/6779/smpc#gref

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3